采用每周顺铂和多西他赛方案对复发和转移性头颈癌进行一线姑息化疗期间的生活质量
Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel.
作者信息
Guntinas-Lichius Orlando, Rühlow Sarah, Veelken Florian, Klussmann Jens Peter
机构信息
Department of Otorhinolaryngology, Friedrich-Schiller-University Jena, Lessingstrasse 2, 07740, Jena, Germany.
出版信息
J Cancer Res Clin Oncol. 2009 Jul;135(7):901-8. doi: 10.1007/s00432-008-0525-9. Epub 2008 Dec 16.
PURPOSE
Quality of life (QOL) should be improved during palliative chemotherapy for end-stage recurrent head and neck cancer. Therefore, we evaluated QOL in head and neck cancer patients during palliative chemotherapy with cisplatin and docetaxel.
METHODS
Thirty patients were included in a prospective study between 2003 and 2007. Response, time-to-progression, overall survival, performance, and toxicity were estimated. QOL was assessed using the EORTC QLQ-C30 and the QLQ-H&N35 questionnaires at baseline, and after each chemotherapy cycle.
RESULTS
The response rate was 17%. Sixty-three percent had stable disease. The median time-to-progression was 3.5 months. The median overall survival was 9.2 months. The QLQ-C30 score constipation and the QLQ-H&N35 scores swallowing, senses problems, speech problems, coughing, weight gain showed significant improvement.
CONCLUSIONS
Only some aspects of QOL are maintained or improved. The QLQ-H&N35 questionnaire seems to be more appropriate to measure QOL, but needs to be improved to account for the peculiarities of modern palliative chemotherapy.
目的
对于晚期复发性头颈癌患者，姑息性化疗期间应改善其生活质量（QOL）。因此，我们评估了顺铂和多西他赛姑息性化疗期间头颈癌患者的生活质量。
方法
2003年至2007年间，30例患者纳入一项前瞻性研究。评估了缓解率、疾病进展时间、总生存期、体能状态和毒性。在基线时以及每个化疗周期后，使用欧洲癌症研究与治疗组织（EORTC）QLQ-C30问卷和QLQ-H&N35问卷评估生活质量。
结果
缓解率为17%。63%的患者疾病稳定。疾病进展的中位时间为3.5个月。总生存期的中位时间为9.2个月。QLQ-C30问卷中的便秘得分以及QLQ-H&N35问卷中的吞咽、感觉问题、言语问题、咳嗽、体重增加得分有显著改善。
结论
仅生活质量的某些方面得以维持或改善。QLQ-H&N35问卷似乎更适合用于测量生活质量，但需要改进以适应现代姑息性化疗的特点。
Zotero 插件